A A Bulanov studies how well the medication Revelise, used for treating ischemic stroke, works in everyday medical practice. Ischemic strokes occur when blood flow to the brain is blocked, causing brain cells to die. His research specifically examines the effectiveness and safety of this treatment in thousands of patients, which helps inform doctors on the best ways to treat stroke victims. He also looks at how various factors, like age and preexisting health conditions, influence recovery after a stroke.
Key findings
In the International PRIMA Study with 2,202 patients, 49.9% had good outcomes at discharge.
The percentage of patients with positive outcomes improved to 66.4% after 90 days.
Revelise significantly reduces stroke-related disabilities, particularly in older patients with other health issues.
Frequently asked questions
Does Dr. Bulanov study ischemic stroke?
Yes, Dr. Bulanov focuses specifically on ischemic stroke and how medications like Revelise can improve patient outcomes.
What is Revelise, and how does it relate to Dr. Bulanov's work?
Revelise is a medication used to treat ischemic stroke, and Dr. Bulanov's research examines its effectiveness and safety in real-world settings.
Are Dr. Bulanov's findings relevant to older stroke patients?
Yes, his research includes many older patients and shows how Revelise can be beneficial for them, even with other health issues.
What type of outcomes did Dr. Bulanov find in his research?
His study found that nearly half of the patients had good outcomes shortly after treatment, with further improvement noted 90 days later.
Publications in plain English
[Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry].
2026
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Martynov MY, Gusev EI, Khasanova DR, Nesterova VN +27 more
Plain English This study looked at how safe and effective a drug called Fortelyzin is for people having an acute ischemic stroke, specifically when used during treatments that involve both thrombolysis and thrombectomy. Out of 1,116 patients, 38% had a good recovery after 90 days, while 29% died in that time. The findings are important because they show that Fortelyzin can be a useful option in treating stroke patients in everyday healthcare settings.
Who this helps: This benefits doctors and patients dealing with acute ischemic strokes.
[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more
Plain English This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues.
Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.
Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma.
2016
Rare tumors
Sayapina MS, Savelov NA, Karseladze AI, Bulanov AA, Tryakin AA +3 more
Plain English This research looks at a rare and aggressive type of cancer called NUT midline carcinoma, which can sometimes appear similar to another cancer called seminoma. The study discusses how these cancers differ from each other and identifies important features that can help doctors make an accurate diagnosis. Understanding these differences is crucial because it can lead to better treatment options and outcomes for patients.
Who this helps: This helps doctors and cancer patients by improving diagnosis and treatment strategies.
[The chemotherapy of nonseminomatous testicular tumors].
1996
Urologiia i nefrologiia
Tiuliandin SA, Bulanov AA, Titov DA, Sokolov AV, Sholokhov VN +1 more
Plain English This study looked at two treatment methods for patients with nonseminomatous testicular tumors. It found that out of 236 patients treated with the VAB-6 combination, 41% achieved complete remission, while 69% of 188 patients treated with etoposide-based regimens (BEP and EP) achieved the same outcome. Although the etoposide treatments caused more side effects, they were more effective, showing that they should be preferred for initial treatment.
Who this helps: This benefits patients with nonseminomatous testicular tumors seeking effective treatment options.